EC
GLUE icon

EntryPoint Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

EntryPoint Capital’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33,219
Closed -$176K – 817
2024
Q3 		$176K Sell
33,219
-31,120
-48% -$157K 0.1% 497
2024
Q2 		$241K Buy
64,339
+48,446
+305% +$247K 0.11% 308
2024
Q1 		$112K Buy
+15,893
New +$94.3K 0.1% 350

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EntryPoint Capital's GLUE Position: Q4 2024 in Review

EntryPoint Capital sold out of Monte Rosa Therapeutics (GLUE) in Q4 2024, closing a stake of 33,219 shares — an estimated $176K sold.

EntryPoint Capital first reported a position in GLUE in Q1 2024 and held it in 3 quarters. The position peaked at $241K in Q2 2024. 104 funds tracked by Wall St. Rank hold GLUE as of Q4 2024.

  • EntryPoint Capital reported no remaining Monte Rosa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 33,219 Monte Rosa Therapeutics shares in Q4 2024, an estimated $176K.
  • EntryPoint Capital first reported a position in Monte Rosa Therapeutics in Q1 2024 and held it in 3 quarters.
  • EntryPoint Capital's Monte Rosa Therapeutics position peaked at $241K in Q2 2024.
  • 104 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.